Westlake Omics (wOmics), founded in July 2020 that focuses on applying mass spectrometry-based proteomics
and other Omics technologies to address pressing clinical needs.
Westlake Omics is committed to making breakthroughs in precision medicine and drug R&D
by unwavering focus on critical issues that impact life and health. This vision is driven by
AI-empowered high-throughput proteomic analysis of minute amounts of clinical specimens
and complementary omic technologies, supported by technological innovation and multi-modal big data.